PCRX Q2 2022 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$169M+24.9% YoY

Gross Profit

$119M70.1% margin

Operating Income

$31M18.4% margin

Net Income

$20M11.7% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$18M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$977M

Stockholders' Equity

$757M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$169M	$136M	+24.9%
Gross Profit	$119M	$100M	+18.4%
Operating Income	$31M	$35M	-10.4%
Net Income	$20M	$19M	+4.2%

Revenue Segments

Product

$169M50%

EXPAREL/bupivacaine liposome injectable suspension

$137M41%

ZILRETTA

$27M8%

Bupivacaine Liposome Injectable Suspension

$956,0000%